Many adults are diagnosed with dementia at later stages or not diagnosed at all, despite how critical early detection is. Why is this the case? Dr. Chin discusses a recent article that highlights some key reasons for this trend and shares an exciting announcement.
What is the current impact of Alzheimer’s disease and related dementias on the United States? To best understand its significance in 2025, we can turn to the Alzheimer’s Association’s Alzheimer’s Disease Facts and Figures report, a comprehensive resource that highlights the effect of Alzheimer’s on individuals, care partners, health care professionals and more. Dr. Heather Snyder from the Alzheimer’s Association joins the podcast to discuss key trends and findings from this year’s report, including insights from their special report on Americans’ attitudes toward early detection and new monoclonal antibody treatments.
Guest: Heather Snyder, PhD, senior vice president, medical & scientific relations, Alzheimer’s Association
Early detection is a top priority in the field of Alzheimer’s research, and one indicator of Alzheimer’s disease is the buildup of tau in the brain. What is tau, though? How can we detect this protein, and what can it tell us about a person’s symptoms or disease progression? Dr. Gil Rabinovici, a leader in the field of brain imaging, joins Dementia Matters this week for an in-depth discussion on the role of tau PET scans in Alzheimer’s disease detection, research and clinical care.
Guest: Gil Rabinovici, MD, professor, Department of Neurology, University of California San Francisco (UCSF), director, UCSF Alzheimer’s Disease Research Center, study chair, Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies, co-principal investigator, Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS)
Receiving a diagnosis of Alzheimer’s disease or a related dementia can be a complicated experience. While some experience relief at being able to put a name to their concerns, many worry about telling loved ones or being treated differently due to the stigma surrounding the word “dementia.” Mike Zuendel joins the podcast to share his experience of being diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and how he’s pushing back against the stigma surrounding dementia. He also talks about how early detection and treatment have allowed him to lead a normal life with cognitive impairment.
Guest: Mike Zuendel, member, board of directors, Banner Alzheimer’s Institute Foundation, member, Alzheimer’s Patient Advisory Board, Center for Information and Study on Clinical Research Participation, founder, Initiative to Change the D-Word, founder, CEO, Legacy Bridge Private Family Offices
What if you could test your cognition from the comfort of your own home using a smartphone? Drs. David Berron and Lindsay Clark have spent years researching cognitive neuroscience, culminating in a 2024 published study investigating the effectiveness of a smartphone app as a tool for detecting cognitive impairment outside of a clinic or research setting. Drs. Berron and Clark join Dementia Matters to discuss how the app and tests were developed, the benefits and drawbacks of this approach and the implications of remote testing in the healthcare field.
Guests: David Berron, PhD, Clinical Cognitive Neuroscience research group leader, German Center for Neurodegenerative Diseases (DZNE), and Lindsay Clark, PhD, licensed neuropsychologist, clinical core co-lead, Wisconsin Alzheimer’s Disease Research Center (ADRC), assistant professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health
Dr. Reisa Sperling returns for another episode of Dementia Matters. After covering her research focused on preclinical Alzheimer’s disease in part one, Dr. Sperling dives deeper into the different factors that can impact cognitive decline and early-stage Alzheimer’s disease and how clinical trials are shaping the field’s understanding of detecting, treating and preventing the disease.
Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School
What if there was a way to detect Alzheimer’s disease before clinical signs and symptoms even appeared? Dr. Reisa Sperling joins Dementia Matters for a two-part series covering her research on detecting and treating Alzheimer’s disease at the earliest possible stage, known as preclinical Alzheimer’s. In this episode, Dr. Sperling goes in-depth on amyloid and tau proteins and the implications on early detection and treatment strategies for Alzheimer’s disease.
Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School
On this episode of Dementia Matters, Dr. Scott Roberts talks about disclosing genetic test results for APOE, a gene that can increase one’s likelihood of developing Alzheimer’s disease. While this information can be concerning, Dr. Roberts shares that it can empower individuals to take the necessary precautions to lower their risk of developing the disease. He discusses the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study, walks us through the APOE disclosure process and shares how it is evolving with the development of new Alzheimer’s treatments.
Guest: Scott Roberts, PhD, interim chair, professor of health behavior & health education, University of Michigan School of Public Health
Research in the field of fluid biomarkers is leading to new developments in Alzheimer’s disease identification, including new tests that can predict Alzheimer’s based on biomarkers in blood. Ahead of his keynote address as part of Alzheimer’s Disease & Related Dementias Research Day on April 5, 2022, Dr. Thomas Karikari joins the podcast to discuss his work with these new blood tests, how accurate they are, and what research needs to be done before they are made available for clinical use.
Guest: Thomas Karikari, PhD, assistant professor, University of Gothenburg, University of Pittsburgh
In a recent study, health economist Lauren Nicholas, PhD, found older adults who go on to be diagnosed with dementia are more likely to miss payments on bills as early as six years before a diagnosis. Dr. Nicholas joins the podcast to discuss her research findings, how financial symptoms could be used as early predictors of dementia, signs that may indicate financial trouble due to dementia, and resources for managing your own or a loved one’s finances early.
Guest: Lauren Nicholas, PhD, associate professor, Johns Hopkins Bloomberg School of Public Health
In the advancing field of dementia research, the rise in genetic and biomarker testing for Alzheimer’s disease creates a need for conversations around how to disclose disease risk to research participants who may be years away from experiencing the symptoms of the disease. Guest Dr. Shana Stites discusses her research that examines public perception of the disease, associated stigma and discrimination, and how the research and medical communities can support people who learn about their Alzheimer’s disease risk profile.
Guest: Shana D. Stites, PsyD, MS, Penn Memory Center, University of Pennsylvania Health System
Research has shown Alzheimer’s disease can be present in the brain decades before symptoms arise. Dr. James Lah discusses how he believes Alzheimer’s disease prevention should start in young and middle adulthood and shares with us what his vision of a cure might look like.
Guest: Dr. James Lah, MD, PhD, Associate Professor of Neurology, Alzheimer’s Disease Investigator, Emory University
Alzheimer’s disease-related changes occur in the brain more than 15 years before a person experiences the memory and personality changes associated with the disease. By studying the disease in its earliest stages, scientists hope to find treatments that can prevent or delay the onset of dementia and memory loss.
Guest: Sterling Johnson, PhD, Clinical Neuropsychologist, Professor of Geriatrics, University of Wisconsin School of Medicine and Public Health, Associate Director of the Wisconsin Alzheimer’s Disease Research Center, Principle Investigator of the Wisconsin Registry for Alzheimer’s Prevention (WRAP) Study